Navigation Links
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
Date:9/10/2009

uren (PTC124(R))

Ataluren is the first investigational new drug designed to restore the formation of a functioning protein in patients with genetic disorders due to a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. Ataluren is currently being investigated for use in patients with nmCF and nmDMD/BMD.

Ataluren has been granted orphan drug status for the treatment of nmCF and nmDMD/BMD by the U.S. Food and Drug Administration (FDA) and the European Commission. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing. The development of ataluren has been supported by the Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation), the FDA Office of Orphan Products Development, the Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and the National Center for Research Resources.

Completed Ataluren Clinical Trials

Data from Phase 2a clinical trials of ataluren in pediatric and adult patients with nmCF show that administration of ataluren results in production of functional CFTR and statistically significant improvements in CFTR chloride channel function in the airways. Ataluren treatment is also associated with reductions in cough frequency and improvements in pulmonary function tests.

Across all ataluren clinical trials to date, including Phase 1 healthy-volunteer trials, ataluren has been generally well tolerated. In Phase 2a trials in nmCF and nmDMD/BMD, adverse events have been largely consistent with background symptoms and have usually been mild. No concerning adverse findings have been identified based on physical examinations, vital sign measurements, electrocardiograms, or laboratory studies. The mean compliance with ataluren therapy has been greater than 90 percent in all
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Just the characterization of being a ... need does not guarantee immediate acceptance. In particular, ... many prior failures is often met with significant skepticism. ... an irony that is often an unappreciated aspect of ... Asymmetrex has found that building acceptance of ...
(Date:5/25/2015)... Phenome Networks, a software-as-a-service plant breeding ... beginning May 31st, of its next-generation Phenome One software. ... Phenome Networks’ lead in the plant breeding market, through ... breeding workflow based on years of experience with plant ... and more. The new version of Phenome One, Phenome ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
Breaking Biology Technology:In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2
... 27, 2011 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, is pleased to announce it has ... Las Vegas laboratory for the National Children,s Leukemia Foundation (NCLF), ...
... 22, 2011 In recognition of the International Year of ... The Changing Role of Chemistry in Drug Discovery ... along with insights from industry experts, the new report forecasts ... the report suggests, a much more targeted, patient-specific approach will ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
Cached Biology Technology:Cord Blood America Announces Exclusive Agreement With National Children's Leukemia Foundation to Store Stem Cells 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... California, San Diego and the University of Hawaii will ... as collaborative ties to Asian institutions to learn more ... off a much-feared pandemic in the region of the ... , "We will use modern high-throughput biology ...
... noise, like the crackle heard on AM radio when lightning ... devices. But within cells, a similar kind of biochemical "noise" ... according to a new study led by a UT Southwestern ... of pharmacology, said his research and that of his colleagues ...
... findings that help shape our understanding of how tool ... that chimpanzees, at least under some conditions, are capable ... prey. The work, reported by Jill Pruetz of Iowa ... Cambridge, will appear online in the journal Current Biology ...
Cached Biology News:Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 2Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 3Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 4Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 5Cells use 'noise' to make cell-fate decisions 2Cells use 'noise' to make cell-fate decisions 3Chimpanzees found to use tools to hunt mammalian prey 2
Request Info...
...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: